» Articles » PMID: 30503695

Estimating HIV and HCV Prevalence Among People Who Inject Drugs in 5 Ukrainian Cities Using Stratification-based Respondent Driven and Random Sampling

Overview
Publisher Elsevier
Date 2018 Dec 4
PMID 30503695
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Ukraine, a country of 45.5 million people, has one of the most volatile HIV and HCV epidemics in the world. In this paper, we estimate the prevalence of HIV and HCV among PWID in five Ukrainian cities.

Methods: A cross-sectional study was conducted in 2014-2015, based on stratified hybrid sampling with random and respondent driven sampling in five cities: Kyiv, Odesa, Mykolaiv, Dnipro and Lviv. Using data on HIV and HCV antibody testing from 1613 respondents, we evaluate selection bias in the sampling methods by analyzing spatial and network patterns of sampling processes. We develop and apply inverse probability weights in order to estimate the HIV and HCV prevalence in each city, as well as in the overall sample.

Findings: The aggregate HIV prevalence for the five cities is 35.1% (95% CI: 29.5%-38.5%) but this varied considerably by city: in Kyiv the HIV prevalence is 26.6% (95% CI: 20.3.8%-33.4%), in Odesa - 38.2% (95% CI: 29.8% and 47.1%), in Mykolaiv - 42.0% (95% CI: 34.3%-49.2%), in Dnipro - 58.8% (95% CI: 52.2%-65.8%), and in Lviv 24.6% (95% CI: 18.8%-30.8%). The aggregate HCV prevalence estimate for the five cities is 58.6% (95% CI: 54.9%-61.7%). The highest HCV prevalence is estimated in Kyiv - 84.8% (95% CI: 78.5%-90.1%). HCV prevalence in Odesa is the lowest and estimated to be 36.5% (95% CI: 29.5%-45.1%), in Mykolaiv - 49.1% (95% CI: 41.5%-57.0%), in Dnipro - 56.1% (95% CI: 50.3%-63.4%) and in Lviv 38.5% (95% CI: 31.8%-45.0%).

Conclusions: Monitoring behavioral and health outcomes of PWID on a regular basis is necessary for determining prevention and treatment priorities for HIV and HCV infections in Ukraine and elsewhere. The heterogeneity of the local epidemics provides insights into the best prevention and treatment strategies to be deployed in low-resource settings.

Citing Articles

Treatment of Hepatitis C Virus Infections Among Patients of Ukrainian Origin During the Influx of War Refugees to Poland.

Flisiak R, Zarebska-Michaluk D, Martonik D, Janocha-Litwin J, Berak H, Sitko M J Clin Med. 2025; 13(24.

PMID: 39768565 PMC: 11727857. DOI: 10.3390/jcm13247641.


A mixed methods exploration of injection drug use risk behaviors and place-based norms in Ukraine.

Owczarzak J, Slutsker J, Mazhnaya A, Tobin K, Kiriazova T J Subst Use Addict Treat. 2023; 154:209135.

PMID: 37544509 PMC: 10543465. DOI: 10.1016/j.josat.2023.209135.


Modelling the impact and cost-effectiveness of non-governmental organizations on HIV and HCV transmission among people who inject drugs in Ukraine.

Stone J, Trickey A, Walker J, Bivegete S, Semchuk N, Sazonova Y J Int AIDS Soc. 2023; 26(4):e26073.

PMID: 37012669 PMC: 10070931. DOI: 10.1002/jia2.26073.


Tracking SARS-COV-2 variants using Nanopore sequencing in Ukraine in 2021.

Yakovleva A, Kovalenko G, Redlinger M, Liulchuk M, Bortz E, Zadorozhna V Sci Rep. 2022; 12(1):15749.

PMID: 36131001 PMC: 9491264. DOI: 10.1038/s41598-022-19414-y.


Tracking SARS-COV-2 Variants Using Nanopore Sequencing in Ukraine in Summer 2021.

Yakovleva A, Kovalenko G, Redlinger M, Liulchuk M, Bortz E, Zadorozhna V Res Sq. 2021; .

PMID: 34873595 PMC: 8647652. DOI: 10.21203/rs.3.rs-1044446/v1.


References
1.
Dolan K, Wirtz A, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner S . Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016; 388(10049):1089-1102. DOI: 10.1016/S0140-6736(16)30466-4. View

2.
Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B . Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 2008; 103(9):1484-92. DOI: 10.1111/j.1360-0443.2008.02249.x. View

3.
Wolfe D, Luhmann N, Harris M, Momenghalibaf A, Albers E, Byrne J . Human rights and access to hepatitis C treatment for people who inject drugs. Int J Drug Policy. 2015; 26(11):1072-80. DOI: 10.1016/j.drugpo.2015.05.007. View

4.
Bazazi A, Crawford F, Zelenev A, Heimer R, Kamarulzaman A, Altice F . HIV Prevalence Among People Who Inject Drugs in Greater Kuala Lumpur Recruited Using Respondent-Driven Sampling. AIDS Behav. 2015; 19(12):2347-57. PMC: 4743744. DOI: 10.1007/s10461-015-1191-y. View

5.
Gile K, Johnston L, Salganik M . Diagnostics for Respondent-driven Sampling. J R Stat Soc Ser A Stat Soc. 2016; 178(1):241-269. PMC: 4877136. DOI: 10.1111/rssa.12059. View